ppt drug therapy for otitis media (nok)

31
KEPANITRAAN KLINIK ILMU PENYAKIT THT RSPAD GATOT SOEBROTO –DITKESAD JAKARTA Periode 16 maret s/d 17 april 2015

Upload: nova-geby-barika

Post on 17-Jan-2016

17 views

Category:

Documents


0 download

DESCRIPTION

PPT

TRANSCRIPT

Page 1: PPT Drug Therapy for Otitis Media (NOK)

KEPANITRAAN KLINIK ILMU PENYAKIT THT

RSPAD GATOT SOEBROTO –DITKESAD JAKARTA

Periode 16 maret s/d 17 april 2015

Page 2: PPT Drug Therapy for Otitis Media (NOK)

DRUG THERAPY FOR

OTITIS MEDIA

Dokter pembimbing:

Dr. Khairan Irmansyah, SpTHT-KL, M.Kes

Disusun oleh:

Nova Geby Barika (UKRIDA) – 11.2013.055

Olivia Papilaya (UKRIDA) – 11.2013.186

Kevin William Hutomo B (UPN) – 131.0221.019

Page 3: PPT Drug Therapy for Otitis Media (NOK)

OTITIS MEDIA

Otitis media (OM) is inflammation or infection of the middle

ear.

It occurs in the area between the ear drum (the end of the

outer ear) and the inner ear, including a duct known as the

Eustachian tube (ET).

http://www.indianjotol.org on Monday, March 16, 2015.

Page 4: PPT Drug Therapy for Otitis Media (NOK)

Acute bacterial OM can cause pain that leads to sleepless

nights for both children and parents, can cause eardrum

perforations, not all of which heal, and can spread to cause

mastoiditis and/or meningitis, brain abscess, and even death

if a severe infection goes untreated long enough.

Eardrum perforations

http://www.indianjotol.org on Monday, March 16, 2015.

Page 5: PPT Drug Therapy for Otitis Media (NOK)

High fever can occur and can cause febrile seizures.

OM is very common in childhood, with the average toddler

having 2-3 episodes a year, almost always accompanied by a

viral upper respiratory infection, mostly the common cold.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 6: PPT Drug Therapy for Otitis Media (NOK)

The rhinoviruses that cause the common cold it promotes the

production of inflammatory mediators, reduced ciliary

clearance, altered bacterial adherence leading to ET

dysfunction, causing swelling and compromise the pressure

equalization, which is one of the physiological functions of the

tube.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 7: PPT Drug Therapy for Otitis Media (NOK)

It has to be remembered that the ET dimension also changes

along with its anatomical and physiological appearance during

the early growth period of the child.

In the newborn, the tube is more slanting making it more

difficult to drain naturally and simultaneously milk may go

into the middle ear on feeding in lying down position.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 8: PPT Drug Therapy for Otitis Media (NOK)

As the early years pass by the superior (upper) part of the tube

ossifies to bone, but the lower remains the same.

Progressions to chronic OM and cholosteatoma are much

more common in this group of people and often have a family

history of middle ear disease.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 9: PPT Drug Therapy for Otitis Media (NOK)

ACUTE OTITIS MEDIA

Acute otitis media (AOM) is most often purely viral and

selflimiting, as is its usually accompanying viral upper respiratory

infection (URI) usually caused by respiratory syncytial virus,

rhinovirus influenza, parainfluenza and adenovirus.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 10: PPT Drug Therapy for Otitis Media (NOK)

If the middle ear, which is normally sterile, becomes

contaminated with bacteria, pus and pressure in the middle ear

may result, and this is termed as acute bacterial otitis media

(OM).

It is necessary to establish whether it is viral or bacterial in

nature.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 11: PPT Drug Therapy for Otitis Media (NOK)

Viral AOM usually presents as congestion and middle ear fluid

accumulation.

The principle bacteriological organism in AOM are

Haemophilus influenzae (42.8%), Streptococcus pneumonia

(35.71%) and Streptococcus pyogenus (7.14%), Moraxella

catarrhalis (21.42).

http://www.indianjotol.org on Monday, March 16, 2015.

Page 12: PPT Drug Therapy for Otitis Media (NOK)

FEATURES

“1st phase” - exudative inflammation lasting 1-2 days, fever, rigors,

meningism (occasionally in children), severe pain (worse at night),

muffled noise in ear (tinnitus), deafness, sensitive mastoid process.

“2nd phase” - resistance and demarcation lasting 3-8 days. Pus and

middle ear exudates, discharges spontaneously through the tympanic

membrane, afterwards pain and fever begin to subside. This phase can

be shortened with therapy.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 13: PPT Drug Therapy for Otitis Media (NOK)

“3rd phase” - healing phase lasting 2-4 weeks. Aural

discharge dries up and hearing improves.

4th phase of complication - If the virulence of an organism is

high, infection may spread to surrounding structures leading to

intra temporal or/and intra cranial complications.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 14: PPT Drug Therapy for Otitis Media (NOK)

OTITIS MEDIA WITH EFFUSION

Otitis media with effusion (OME), also called serous or

secretory otitis media (SOM), is a collection of fluid within the

middle ear space as a result of the negative pressure due to

altered Eustachian tube (ET) function.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 15: PPT Drug Therapy for Otitis Media (NOK)

The diagnosis is confirmed by tympanometry which shows “B”

type curve and absent reflex. Myringotomy finally confirms it.

Pneumatic otoscopy and acoustic reflexometry are important

diagnostic tool.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 16: PPT Drug Therapy for Otitis Media (NOK)

Fluid in the middle ear may cause conductive hearing

impairment, but only when it interferes with the normal

vibration of the eardrum by sound waves.

Over weeks and months, middle ear fluid can become thick

and glue-like (thus the name glue ear), which increases the

likelihood of conductive hearing impairment.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 17: PPT Drug Therapy for Otitis Media (NOK)

CHRONIC SUPPURATIVE OTITIS MEDIA

Chronic suppurative OM presents as a central, marginal or

attic perforation (hole) in the tympanic membrane and active

bacterial infection within the middle ear space for more than

4-6 weeks with pus that drains to the outside of the ear

(otorrhea), The purulence may be minimal enough to only be

seen on examination using an otoscope (cholesteatoma).

http://www.indianjotol.org on Monday, March 16, 2015.

Page 18: PPT Drug Therapy for Otitis Media (NOK)

Etiologically Staphylococcus aureus 30.7%, betahemolytic

streptococci 26%, Pseudomonas aeruginosa 16%, Escherichia

coli 10.6% and Klebsiella species 7% and has been observed by

the author as a causative organism.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 19: PPT Drug Therapy for Otitis Media (NOK)

MANAGEMENT AND TREATMENT OF OTITIS MEDIA

Medical management of OM is actively debated in the medical

literature, primarily because of a dramatic increase in AOM

prevalence over the past 10 years caused by drug resistant S.

pneumonia and beta-lactamase–producing H. Influenzae or M.

Catarrhalis, S. pneumonia.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 20: PPT Drug Therapy for Otitis Media (NOK)

Beta-lactamases are enzymes that hydrolyze amoxicillin and

some, but not all, oral cephalosporins, leading to in vitro

resistance to these drugs.

As a result, empiric antibiotic therapy for this disease has

become more complex.

Many opinions have been expressed regarding which drugs are

best for first and secondline therapy or whether antibiotics

should be prescribed in all patients with AOM.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 21: PPT Drug Therapy for Otitis Media (NOK)

GUIDELINES FOR MANAGEMENT OF ACUTE OTITIS MEDIA

Amoxicillin is the drug of choice which may be prescribed for:

unilateral AOM with symptoms, moderate to severe otalgia

with pyrexia

In bilateral cases even without pyrexia.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 22: PPT Drug Therapy for Otitis Media (NOK)

Dosage: Amoxicillin 80-90 mg/kg/day along with 6.4

mg/kg/day potassium clavunate/clavulanic.

The Authors choice is cefuroxime axetil 30 mg/day with

potassium clavunate 6.4 mg/kg/day.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 23: PPT Drug Therapy for Otitis Media (NOK)

Supportive therapy

Nasal decongestants, analgesics tincture benzoin steam

inhalations enhances the recovery.

Severe case Analgesic Narcotic

Steroids use controversial

Methyl prednisolone and deflazacort has been used with

some success

http://www.indianjotol.org on Monday, March 16, 2015.

Page 24: PPT Drug Therapy for Otitis Media (NOK)

MEDICAL THERAPY FOR OTITIS MEDIA WITH EFFUSION

Most cases of OME occur after an episode of AOM, and good

number of patients develops a SOM middle ear effusion (MEE).

OME are associated with conductive hearing loss, averaging

approximately 25 dB.

Most cases of OME resolve spontaneously

http://www.indianjotol.org on Monday, March 16, 2015.

Page 25: PPT Drug Therapy for Otitis Media (NOK)

Medical management: Antimicrobials,

antihistaminedecongestants, intranasal and systemic steroids,

nonsteroidal anti-inflammatory drugs, mucolytics and

aggressive management of allergic symptom

If OME is unresponsive to medical therapy and with an

MEE that persists more than 12 weeks tympanocentesis

http://www.indianjotol.org on Monday, March 16, 2015.

Page 26: PPT Drug Therapy for Otitis Media (NOK)

SURGICAL INTERVENTION Integrate surgical management of AOM and OME with medical

treatment may be a modality for prompt relief and to avoid

complications.

Indications:

Severe Otalgia

Unresponsive antimicrobial therapy

OM associated with supurative complication

OM in newborn, sick neonate, immunologically deficient

http://www.indianjotol.org on Monday, March 16, 2015.

Page 27: PPT Drug Therapy for Otitis Media (NOK)

SPECIAL CASES: CLEFT PALATE

In cleft palate patients because of inherent ETD and increased

risk of OM, the TT may be placed with initial lip repair or may be

prior to palate repair.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 28: PPT Drug Therapy for Otitis Media (NOK)

SPECIAL CASE: DOWN’S SYNDROME

Children with DS often exhibit ETD, conductive and

sensorineural hearing loss, external auditory canal (EAC)

stenosis, and subtle immunologic deficiencies high risk of

personality and child development.

Hence myringotomy/TT may be required at an early stage.

To prevent recurrent otitis externa, wax impaction or

cholesteatoma of EAC, canaloplasty should be performed.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 29: PPT Drug Therapy for Otitis Media (NOK)

The incidence of OM and deafness could be prevented by

maternal education. Spesifically:

Contributing factors

Early management modalities of ear involvement

Public health efforts should be made to promote breast

feeding:

Inc. breastfeeding position

Avoid digital sucking and pacifiers

http://www.indianjotol.org on Monday, March 16, 2015.

Page 30: PPT Drug Therapy for Otitis Media (NOK)

Dairy products discouraged and abandoned.

Smoking should be discouraged and no smoking around the

children.

Harsh climate, crowded housing, poor sanitary

conditions, and lack of personal hygiene should be

adequately dealt with.

Exposure to cold to avoided in winter months which may

lead to silent OME.

http://www.indianjotol.org on Monday, March 16, 2015.

Page 31: PPT Drug Therapy for Otitis Media (NOK)